BRAF and melanoma: This retrospective study investigated outcomes of anti‐programmed death receptor‐1 monotherapy and targeted therapy in the first‐line setting in patients with metastatic BRAF‐mutated melanoma, focusing on clinical and laboratory parameters associated with treatment outcome.